Letrozole Shortage: What Providers and Prescribers Need to Know in 2026

Letrozole (Femara) is one of the most widely prescribed adjuvant endocrine therapies for hormone receptor-positive breast cancer and the preferred first-line ovulation induction agent for PCOS-related infertility. While it is not currently on the FDA's national shortage list as of 2026, providers across the country are fielding patient calls about difficulty obtaining the drug at their usual pharmacy. This guide is designed to help oncologists, gynecologic oncologists, reproductive endocrinologists, and general practitioners navigate these availability challenges effectively.

Current Supply Landscape: What Providers Should Know

Letrozole's multi-manufacturer generic market (including Breckenridge Pharmaceutical and others) provides supply chain resilience that single-source drugs lack. However, this does not make the drug immune to regional availability gaps. The following dynamics are currently affecting supply:

Periodic lot recalls: Individual manufacturers have issued recalls on specific lots due to manufacturing quality issues, temporarily pulling supply from pharmacies that relied on that manufacturer.

Increased demand: Letrozole's dual role as both a standard-of-care breast cancer treatment and the preferred off-label fertility agent for PCOS has significantly expanded the patient population, increasing baseline demand across all markets.

Distributor transition periods: Pharmacy chains periodically switch generic manufacturer contracts, creating brief gaps at affected stores during the transition.

Clinical Implications of Therapy Interruptions

For oncology patients, even brief interruptions in adjuvant endocrine therapy are clinically significant. Letrozole's mechanism depends on continuous suppression of estrogen synthesis to deprive hormone receptor-positive tumor cells of their growth stimulus. While a few missed doses are unlikely to cause immediate harm, providers should be aware that non-adherence to adjuvant endocrine therapy is associated with increased recurrence risk in the literature.

For fertility patients, the window is even tighter. Letrozole for ovulation induction is typically administered on cycle days 3-7, and missing this window means losing the entire treatment cycle. This can be particularly distressing for patients undergoing timed intercourse or IUI protocols.

Therapeutic Alternatives: When Is Switching Appropriate?

For breast cancer patients who cannot access Letrozole within a clinically acceptable timeframe:

Anastrozole (Arimidex): The most clinically equivalent alternative. Both are non-steroidal AIs with similar mechanisms. The FACE trial and other studies have found no significant difference in disease-free survival. Anastrozole is dosed at 1 mg daily. Switching is generally straightforward with minimal re-titration required.

Exemestane (Aromasin): A steroidal AI dosed at 25 mg daily with food. Useful in patients who experienced significant musculoskeletal side effects on non-steroidal AIs, as the different binding mechanism may be better tolerated. Recent JAMA Network Open data suggests slightly lower 8-year DFS and OS versus anastrozole or letrozole, but the absolute difference is modest and clinically nuanced.

Tamoxifen: Appropriate as a short-term bridge for postmenopausal patients if an AI cannot be obtained within 2-4 weeks, or as the preferred long-term agent for patients who remain premenopausal or cannot tolerate AIs. Tamoxifen is widely available with no recent supply issues.

Strategies for Improving Patient Access to Letrozole

Providers can take several proactive steps to help patients avoid therapy interruptions:

Prescribe 90-day supplies via mail-order pharmacy — reduces refill frequency and sidesteps local availability issues. Ensure the prescription specifies quantity clearly.

Recommend patients refill proactively — advise patients not to wait until they are out of medication. Most insurance plans allow refills when 7-10 days of supply remains.

Direct patients to medfinder — medfinder.com calls pharmacies on behalf of patients to locate which ones can fill their prescription, reducing the burden on patients and office staff fielding pharmacy location calls.

Maintain awareness of local pharmacy inventory — develop a short list of pharmacies in your area that reliably stock Letrozole. Share this with your care coordination team for quick reference when patients call.

38,353+ patients found their medications in stock

38K+

Find Letrozole In Stock Today →

Counseling Patients Who Are Worried About Supply

Patients on long-term adjuvant therapy understandably become anxious when they cannot find their medication. Key counseling points:

Letrozole is not in a national shortage — it is available nationally, just unevenly distributed at the local level

A missed dose or two is unlikely to cause immediate harm, but prolonged gaps should be avoided

The clinical team is prepared to help them find alternatives if needed — they are not alone in navigating this

If Letrozole truly cannot be found within a few days, a clinically equivalent switch to anastrozole is available

Resources for Your Practice

medfinder offers a provider-facing platform at medfinder.com/providers that helps your patients locate hard-to-find medications at pharmacies near them. Directing patients here can reduce the volume of "I can't find my medication" calls your staff handles.

See also: How to Help Your Patients Find Letrozole in Stock: A Provider's Guide.